In a randomized clinical trial performed in 557 HER2-low previously treated metastatic breast cancers, T-DXd resulted in significantly longer progression-free survival (PFS) and overall survival (OS) than the physician’s choice of chemotherapy [21]. Here, ERBB2 is linked to breast carcinoma.